PT-141 Literature Review: Key Preclinical Papers
This literature review synthesizes published preclinical evidence evaluating PT-141 (Bremelanotide), a synthetic cyclic heptapeptide melanocortin receptor agonist. Derived from Melanotan II, PT-141 has been extensively evaluated in animal models to elucidate central nervous system signaling pathways, receptor binding kinetics, and neuroendocrine responses linked to sexual-health pathways. All data discussed herein reflect strictly in vitro and animal research parameters.
Quick answer
This literature review synthesizes published preclinical evidence evaluating PT-141 (Bremelanotide), a synthetic cyclic heptapeptide melanocortin receptor agonist. Derived from Melanotan II, PT-141 has been extensively evaluated in animal models to elucidate central nervous system signaling pathways, receptor binding kinetics, and neuroendocrine responses linked to sexual-health pathways. All data discussed herein reflect strictly in vitro and animal research parameters.
Key takeaways
- [PT-141](/research-peptides/pt-141) (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH), chemically known as Bremelanotide, originated from structural refinement efforts aimed at isolating the central nervous system activity of earlier melanocortin analogues.
- Published [pt-141](/research-peptides/pt-141) studies evaluate the peptide's binding profile across five distinct G-protein coupled melanocortin receptors (MC1R through MC5R).
- A central focus of preclinical [pt-141](/research-peptides/pt-141) studies has been mapping the neuroanatomical loci responsible for its physiological responses.
- To understand the unique profile of Bremelanotide, researchers routinely benchmark it against other peptides within the melanocortin class.
Structural Origins and Molecular Evolution of PT-141
PT-141 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH), chemically known as Bremelanotide, originated from structural refinement efforts aimed at isolating the central nervous system activity of earlier melanocortin analogues. Researchers initially derived the molecule from Melanotan II by preserving the core cyclic pharmacophore—specifically the His-D-Phe-Arg-Trp sequence—while replacing the terminal amide group with a free carboxylic acid at the C-terminus. This structural modification altered both its lipophilicity and its pharmacological profile across melanocortin receptor subtypes.
Early literature established that while parent α-melanocyte-stimulating hormone (α-MSH) is a linear peptide subject to rapid enzymatic degradation by neutral endopeptidases, the lactam bridge structure of PT-141 imparts significant conformational stability. In preclinical stability trials, the cyclic structure demonstrated resistance to rapid proteolysis, permitting sustained binding interactions in receptor-binding assays and in vivo rodent paradigms. Laboratory investigations focused on PT-141 10mg frequently analyze how these structural parameters influence peptide stability across varying temperature and pH ranges.
Receptor Subtype Affinity and Binding Kinetics
Published pt-141 studies evaluate the peptide's binding profile across five distinct G-protein coupled melanocortin receptors (MC1R through MC5R). Radioligand displacement assays using standard cell lines expressing recombinant human and rodent melanocortin receptors demonstrate that PT-141 exhibits primary agonist activity at MC4R and MC3R, with lower affinity for MC1R and minimal interaction at MC2R (the adrenal ACTH receptor) or MC5R.
Competitive binding studies indicate an inhibition constant (Ki) for MC4R in the low nanomolar range. Activation of MC4R by PT-141 initiates intracellular signaling via Gs-protein coupling, stimulating adenylate cyclase and causing rapid intracellular cyclic adenosine monophosphate (cAMP) accumulation. In vitro functional bioassays confirm that Bremelanotide acts as a full agonist at MC4R, reaching maximal cAMP stimulation comparable to native α-MSH, but with altered receptor desensitization and internalization dynamics.
Central Nervous System Pathways and Hypothalamic Signaling
A central focus of preclinical pt-141 studies has been mapping the neuroanatomical loci responsible for its physiological responses. Unlike peripherally acting vasoactive agents, PT-141 acts primarily within the central nervous system. Immediate-early gene mapping via c-Fos expression in rodent brains following systemic or central administration revealed targeted neural activation within key hypothalamic and limbic structures.
Specifically, published studies demonstrate heightened c-Fos immunoreactivity within the medial preoptic area (mPOA), the paraventricular nucleus of the hypothalamus (PVN), and the ventral tegmental area (VTA). Microinjection studies in male and female rat models confirmed that direct microinfusion of PT-141 into the mPOA or PVN triggered specific behavioral and neuroendocrine responses, whereas lesioning these central structures attenuated peptide-induced physiological outcomes. This body of research confirmed that PT-141 operates upstream of peripheral autonomic output by modulating central melanocortin circuits.
Comparative Analysis: PT-141 vs. Related Melanocortin Agonists
To understand the unique profile of Bremelanotide, researchers routinely benchmark it against other peptides within the melanocortin class. In published comparative bioassays, PT-141 is frequently evaluated alongside parent compounds and truncated derivatives to assess differences in receptor selectivity, central activation, and peripheral pigmentary responses.
When evaluating the broader catalog of research peptides, researchers observe distinct functional divisions within the melanocortin family. For example, while Melanotan II exhibits potent affinity for both MC1R and MC4R—inducing significant peripheral melanogenesis alongside central signaling—PT-141 demonstrates reduced peripheral MC1R activity relative to its central MC4R/MC3R potency. Furthermore, comparison with native linear α-MSH analogues highlights that the cyclic lactam structure of PT-141 substantially extends half-life in physiological buffers, avoiding the rapid enzymatic clearance typical of linear peptides in experimental models.
Preclinical Behavioral Frameworks and Endpoint Quantification
Preclinical evaluation of PT-141 relies on quantitative animal behavioral models designed to measure central drive and autonomic responses linked to sexual-health pathways. In male rodent paradigms, researchers monitor parameters such as latency to initial mounting, intromission frequency, and intracavernosal pressure (ICP) elevation. Studies utilizing telemetric ICP sensors recorded dose-dependent increases in peak intracavernosal pressure following central or subcutaneous administration of Bremelanotide.
In female rodent bioassays, experimental endpoints focus on appetitive and consummatory behaviors. Published papers report that PT-141 administration increased appetitive solicitations (such as hops, darts, and solicitous visits) in wild-type female rats exposed to male conspecifics. Crucially, these behavioral responses were abolished in MC4R knockout mouse models or when co-administered with selective MC4R antagonists (e.g., SHU9119), verifying that the observed behavioral outputs are specifically mediated through central MC4R signaling pathways.
Cardiovascular and Autonomic Physiological Endpoints
In addition to central behavioral parameters, published literature extensively documents the hemodynamic effects of melanocortin receptor activation. Because MC4R receptors are expressed in brainstem centers regulating autonomic outflow (such as the nucleus tractus solitarii), systemic administration of melanocortin agonists can influence systemic arterial pressure and heart rate.
Telemetry studies in conscious, unrestrained rat and canine models indicate that administration of PT-141 produces transient, dose-dependent elevations in mean arterial pressure (MAP) accompanied by mild decreases or variable changes in heart rate. Researchers note that these pressor responses are centrally mediated, driven by increased sympathetic tone. Assessing cardiovascular parameters remains a standard requirement in preclinical study design when evaluating central melanocortin pathway activation.
Solubilization, Reconstitution, and Experimental Handling Standards
Achieving consistent results in pt-141 studies requires rigorous adherence to laboratory preparation standards. Lyophilized PT-141 acetate salt demonstrates strong solubility in sterile aqueous buffers. Standard laboratory protocols specify reconstitution using Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline depending on the targeted assay endpoint and cell culture sensitivity.
Researchers performing quantitative dilutions utilize tools like a laboratory reconstitution calculator to determine precise molar concentrations for in vitro binding assays or microinfusion protocols. Literature emphasizes avoiding vigorous mechanical agitation during dissolution to prevent peptide aggregation or secondary structure denaturation. Stock solutions stored at 2–8°C maintain chemical stability over short experimental windows, whereas long-term preservation of reconstituted aliquots requires -20°C or -80°C storage to prevent hydrolytic degradation.
Analytical Quality Control and Material Verification
The validity of published preclinical data directly depends on the chemical purity and structural integrity of the synthesized peptide. Minor impurities, truncated sequences, or trace endotoxin contamination can confound receptor binding assays and trigger non-specific cellular responses in sensitive bioassays.
PX1 Research enforces stringent quality assurance standards for all research compounds. Every lot of PT-141 manufactured in our USA-based, GMP-compliant facilities undergoes rigorous analytical verification. Purity is validated via high-performance liquid chromatography (HPLC), while molecular weight and structural identity are verified through mass spectrometry (MS). Detailed documentation is accessible via our public Certificate of Analysis (COA) database. Furthermore, lot-specific testing ensures low endotoxin levels (verified by Limulus Amebocyte Lysate testing), protecting cell culture and animal models from confounding inflammatory artifacts. All orders ship directly from our California and Arizona fulfillment centers with same-day dispatch for orders placed Monday through Friday.
Frequently Asked Questions
What primary receptor targets are evaluated in PT-141 studies?
Preclinical studies primarily investigate PT-141 as an agonist at the MC4R and MC3R receptor subtypes within the central nervous system. It exhibits lower affinity for MC1R and negligible interaction with MC2R or MC5R.
How does PT-141 differ structurally from Melanotan II?
PT-141 is a structural analogue of Melanotan II where the C-terminal amide is replaced with a hydroxyl group, forming a free carboxylic acid. This modification reduces peripheral MC1R activity while preserving potent central MC4R activation.
What central brain regions are activated by PT-141 in rodent models?
c-Fos expression mapping in animal studies shows that PT-141 selectively activates neurons in the medial preoptic area (mPOA), paraventricular nucleus of the hypothalamus (PVN), and ventral tegmental area (VTA).
How is PT-141 prepared for in vitro cell culture assays?
For laboratory research, lyophilized PT-141 is reconstituted using sterile saline or laboratory-grade solvents. Researchers calculate exact concentrations using specialized tools to ensure precise nanomolar dosing in receptor assays.
What quality assurance documentation does PX1 Research provide for PT-141?
Every lot of PT-141 provided by PX1 Research includes a lot-specific Certificate of Analysis (COA) confirming peptide purity (>98%) via HPLC and verifying correct sequence identity through Mass Spectrometry (MS). Endotoxin testing confirms suitability for sensitive experimental models.
What storage conditions are recommended for lyophilized PT-141?
Lyophilized PT-141 should be stored at -20°C in a desiccated container to preserve peptide stability. Avoid repeated freeze-thaw cycles after reconstitution.
What cardiovascular endpoints are monitored during PT-141 animal studies?
Preclinical telemetry models frequently measure mean arterial pressure (MAP) and heart rate, as central MC4R activation can induce transient pressor responses mediated by sympathetic nervous system stimulation.
Is PT-141 approved for human consumption or clinical use from PX1 Research?
No. All compounds supplied by PX1 Research, including PT-141, are intended strictly for laboratory research use only in scientific research settings. They are not for human or veterinary diagnostic, therapeutic, or clinical application.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.